注射用灯盏花素治疗6 795例脑梗死患者真实世界特征分析
Real-world characteristics of breviscapine injection for cerebral infarction in 6, 795 patients
- 现代中医临床 2022年29卷第4期 页码：8-16
- 作者机构：
1.中国中医科学院中医临床基础医学研究所 北京 100700
2.中国中医科学院西苑医院
3.中国人民大学统计学院
- 作者简介：
宋清雅，女，在读硕士生
# 黎元元，女，博士，研究员，硕士生导师，E-mail：chibjyy@163.com
- 基金信息：国家重点研发计划项目资助(2018YFC1707400)
DOI：10.3969/j.issn.2095-6606.2022.04.002
中图分类号： R255.2纸质出版日期：2022-07-30，
收稿日期：2021-03-15，
- 稿件说明：
移动端阅览
宋清雅, 魏瑞丽, 谢雁鸣, 等. 注射用灯盏花素治疗6 795例脑梗死患者真实世界特征分析[J]. 现代中医临床, 2022,29(4):8-16.
Qingya SONG, Ruili WEI, Yanming XIE, et al. Real-world characteristics of breviscapine injection for cerebral infarction in 6, 795 patients[J]. Modern Chinese Clinical Medicine, 2022,29(4):8-16.
宋清雅, 魏瑞丽, 谢雁鸣, 等. 注射用灯盏花素治疗6 795例脑梗死患者真实世界特征分析[J]. 现代中医临床, 2022,29(4):8-16. DOI： 10.3969/j.issn.2095-6606.2022.04.002.
Qingya SONG, Ruili WEI, Yanming XIE, et al. Real-world characteristics of breviscapine injection for cerebral infarction in 6, 795 patients[J]. Modern Chinese Clinical Medicine, 2022,29(4):8-16. DOI： 10.3969/j.issn.2095-6606.2022.04.002.
摘要
目的
2
分析真实世界中注射用灯盏花素治疗脑梗死患者的临床特征及用药特点，为临床提供参考。
方法
2
以2002—2015年全国37家三级甲等医院6 795例住院期间使用注射用灯盏花素的脑梗死患者为研究对象，应用统计软件SAS 9.3对患者的一般信息、诊断信息及用药信息等进行频次及百分率的描述性分析，应用交叉列联法对注射用灯盏花素的使用剂量与疗程的关系进行分析。
结果
2
6 795例中男女比例约为1.39∶1；65～80岁者占45.95%；职业以工人最多，占36.73%；入院科室以神经内科最多，占34.64%；入院季节以春季最多，占26.65%，寒露节气入院率最高，占5.71%；入院病情以一般者最多，占73.33%；住院时间以15～28 d最多，占33.20%。患者的合并疾病以原发性高血压病最多，占40.71%；中医证候以痰瘀阻络证最多，占18.16%。注射用灯盏花素的给药途径以静脉滴注最多，共9 800次，占89.01%，其中未超说明书剂量使用者占47.67%，超说明书剂量使用者占52.32%。用药时间平均为(11.12±9.63)d。治疗脑梗死合并使用相关西药主要包括降压类、抗血小板聚集类、保护神经类、改善脑供血类西药。治疗脑梗死合并使用相关中药主要包括活血化瘀类、益气养阴类、开窍类、益气扶正类、平补肝肾类、化痰降脂类中药。治愈患者中，未超说明书常用剂量使用者占44.84%，超说明书常用剂量使用者占55.16%。好转患者中，未超说明书常用剂量使用者占52.91%，超说明书常用剂量使用者占47.09%。
结论
2
真实世界中，注射用灯盏花素常用于治疗脑梗死，多与降压类西药、活血化瘀类中药合并使用。注射用灯盏花素超说明书常用剂量使用时的疗效及其与糖皮质激素类药物、活血化瘀类药物合并使用时的安全性有待进一步研究。
Abstract
Objective
2
The clinical characteristics and medication features of patients with cerebral infarction in the real world were analyzed to provide references for clinical application.
Methods
2
The 6
795 patients with cerebral infarction who were hospitalized during 2002-2015 in 37 tertially-A hospitals were included as participants
and SAS 9.3 was used to analyze frequency and percentage
and the relationship between dosage and duration.
Results
2
In 6
795 cases
the male-female ratio was 1.39∶1. People aged between 65 and 80 years old accounted for 45.95%
and workers
who were the most
accounted for 36.73%. The neurology department was the department with the most admissions
accounting for 34.64%
and the spring was the season with most admissions
acounting for 26.65%. The admission rate of Cold Dew solar term was the highest
accounting for 5.71%. The condition on admission was common
accounting for 73.33%. The hospitalization duration was mostly 15-28 days
accounting for 33.20%. Primary comobidity was hypertension
accounting for 40.71%. Among all traditional Chinese medicine patterns
the pattern of phlegm and blood stasis blocking collaterals was the most common
accounting for 18.16%.The administration of breviscapin for injection was the most frequently used intravenous drip
totaling 9
800 times
accounting for 89.01%
of which 47.67% were not and 52.32% had off-label doses.The average medication days were 11.12 ± 9.63 d. The treatment of cerebral infarction mainly included antihypertensive drugs
antiplatelet aggregation drugs
neuroprotection drugs
and improvement of cerebral blood supply drugs. The treatment of cerebral infarction with the combination of related traditional Chinese medicine mainly included promoting blood circulation and removing blood stasis
nourishing Qi and Yin
resusinating
nourishing Qi and strengthening Qi
pacifying and tonifying the liver and kidney
resolving phlegm and lowering lipid. Among the cured patients
44.84% of users were within use-standard dosage
and 55.16% were over-standard dosage. Among patients with improved conditions
52.91% were within use-standard dosage
and 47.09% were over-standard dosage.
Conclusions
2
In the real world
breviscapin for injection is often used for the treatment of cerebral infarction
which is mostly combined with Western medicine of hypotensor and traditional Chinese medicine of promoting blood circulation and removing blood stasis. Further research is needed to study the efficacy of breviscapine for injection and its safety when combined with glucocorticoids and medicine of promoting blood circulation and removing blood stasis.
关键词
注射用灯盏花素脑梗死真实世界
Keywords
breviscapine for injectioncerebral infarctionreal world
references
黎元元，郭蓉娟，谢雁鸣，等.注射用灯盏花素临床应用专家共识[J].中国中药杂志，2020,45(10):2296-2299.
LIU X D, YAO L, SUN D, et al. Effect of breviscapine injection on clinical parameters in diabetic nephropathy: a meta-analysis of randomized controlled trials[J].Experimental and Therapeutic Medicine, 2016,12(3):1383-1397.
刘梦琳，樊根豪，安瑞丽，等.灯盏花素注射液辅助治疗急性脑梗死的Meta分析[J].中成药，2020,42(4):921-926.
段江南，高阳，谢雁鸣，等.真实世界中使用醒脑静注射液致肾功能异常患者的临床特征分析[J].现代中医临床，2021,28(2):9-15.
北京协和医院世界卫生组织国际分类家族合作中心.疾病和有关健康问题的国际统计分类：第十次修订本[M].北京：人民卫生出版社，2008.
国家市场监督管理总局，国家标准化管理委员会.中医临床诊疗术语 第2部分：证候：GB/T 16751.2—2021[S].北京：中国标准出版社，2021.
郭珍平，吴珊，张敏，等.急性脑梗死患者的危险因素分析[J].癫痫与神经电生理学杂志，2020,29(3):162-166.
GLEBE S, COCKCROFT N, HEWITT K, et al.Cigarette smoke extract counteracts atheroprotective effects of high laminar flow on endothelial function[J].Redox biology, 2017(12):776-786.
LEE K W, LIP G Y.Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review[J].Archives of Internal Medicine, 2003,163(19):2368-2392.
周翔，吉维忠，胡全忠.进展性脑梗死与脑梗死分型及其危险因素的研究进展[J].中国现代医药杂志，2017,19(9):84-87.
杨阳，孙博谦.进展性脑梗死危险因素研究进展[J].中国保健营养，2020,30(22):49.
贾建平，陈生弟.神经病学[M].北京：人民卫生出版社，2018.
陈祖芝，梅文丽，任志霞，等.急性脑梗死静脉溶栓后症状性脑出血的危险因素研究进展[J].中国实用神经疾病杂志，2017,20(2):119-121.
张冰琳.缺血性脑卒中的病理环节及实验研究[J].临床医药文献电子杂志，2020,7(80):191-192.
中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志，2018,51(9):666-682.
袁明皓.急性脑梗死患者并发肺部感染的危险因素分析[D].重庆：重庆医科大学，2019.
孙明秀，左东辉，吴宇欣.脑梗死患者合并肺部感染的危险因素及预防措施[J].湖南师范大学学报(医学版)，2020,17(5):87-89.
徐功蒲.急性脑梗死后肺部感染危险因素分析[D].泸州：西南医科大学，2019.
杨宝峰，陈建国.药理学[M].北京：人民卫生出版社，2018:233.
张富慧，张富全，郭娟，等.参麦注射液联合灯盏花素注射液治疗急性缺血性脑卒中的临床研究[J].中西医结合心脑血管病杂志，2020,18(13):2150-2153.
巩雷.缺血性脑卒中后胃肠道并发症的研究进展[J].中国实用医药，2020,15(24):190-192.
黄萍，张彩艳.缺血性脑卒中后便秘相关因素的分析评价及护理[J].世界华人消化杂志，2014,22(22):3365-3368.
郝新宇，于士柱.复发性缺血性卒中相关危险因素研究进展[J].中国现代神经疾病杂志，2017,17(10):765-770.
江颖，方兴，张永全.活血化瘀法治疗缺血性卒中的研究进展[J].世界中医药，2016,11(5):936-940.
郑欢.通腑法治疗急性缺血性脑卒中疗效的Meta分析[D].武汉：湖北中医药大学，2016.
陈爱军，秦桂华.急性期高血压性脑卒中血压水平与预后的相关性分析[J].医药前沿，2020,10(5):84-85.
MAHESH K, NEGAR A, LAURA C G, et al.Blood pressure reduction in hypertensive acute ischemic stroke patients does not affect cerebral blood flow[J].Journal of Cerebral Blood Flow and Metabolism, 2019,39(9):1878-1887.
HE J, ZHANG Y H, XV T, et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial[J].Journal of the American Medical Association, 2014,311(5):479-489.
XV T, ZHANG Y H, BU X Q, et al. Blood pressure reduction in acute ischemic stroke according to time to treatment: a subgroup analysis of the China antihypertensive trial in acute ischemic stroke trial[J].Journal of Hypertension, 2017,35(6):1244-1251.
陈丽萍.急性脑卒中急性期血压调控与预后的多因素相关性研究[J].临床医药文献电子杂志，2018,5(8):29.
李丽.脑梗死后癫痫危险因素的临床分析[D].太原：山西医科大学，2016.
宋礼.灯盏花素联合波立维对脑梗塞患者血流变的影响及疗效观察[J].国际医药卫生导报，2018,24(3):394-396.
0
浏览量
127
下载量
0
CSCD
- 网络PDF下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies